Rakovina Therapeutics Inc. reported a net loss of $1,781,757 for Q3 2025, with R&D expenses at $1,102,371 and G&A expenses at $539,174. Cash and cash equivalents stood at $822,293 as of September 30, 2025. The company’s executive chairman highlighted recent scientific and corporate milestones, positioning Rakovina for growth in 2026.

Recent corporate highlights include presentations at key industry conferences, such as the Society for Neuro-Oncology Annual Meeting, where Rakovina showcased its ATR and PARP1 programs. The company’s ATR compounds have been confirmed as dual ATR/mTOR inhibitors, showing promise for treating PTEN-deficient solid tumors with high incidence of brain metastases.

Financially, Rakovina’s working capital deficit was $489,279 as of September 30, 2025, with total assets at $5,267,709 and total liabilities at $3,380,019. The company reported a net loss of $1,781,757 for the quarter, with basic and diluted loss per share at $0.08.

Looking ahead, Rakovina Therapeutics aims to advance its DNA-damage response inhibitors into human clinical trials through collaborations with pharmaceutical partners. The company leverages AI-powered platforms for drug discovery, enabling rapid optimization of drug candidates. Interested parties can access the company’s financial statements on its website.

Rakovina Therapeutics cautions that its forward-looking statements are subject to risks and uncertainties, impacting the achievement of proposed business plans. Factors such as regulatory changes, economic conditions, and competition could affect actual results. The company undertakes no obligation to update these statements, emphasizing the importance of considering all risk factors in investment decisions. For further information, contact Director of Corporate Development, Michelle Seltenrich, at [email protected] or 778-773-5432.

Read more at GlobeNewswire: Rakovina Therapeutics Announces Three-Month Q3 ended